Case report reveals lung adenocarcinoma as a second malignancy in a patient with CLL, suggesting close monitoring is necessary.
Chronic lymphocytic leukemia (CLL) and its variant, small lymphocytic lymphoma (SLL), are common adult leukemias characterized by the accumulation of mature monoclonal B lymphocytes. CLL primarily involves peripheral blood, spleen, and lymph nodes, whereas SLL predominantly affects lymph nodes. Patients with CLL/SLL are at increased risk of developing second primary malignancies, including lung cancer, highlighting the need for ongoing surveillance. We report the case of an 83-year-old man with a history of CLL/SLL who developed pulmonary adenocarcinoma. He presented weight loss and constitutional symptoms; imaging revealed retroperitoneal and mesenteric lymph node conglomerates along with a lung lesion. Histopathology confirmed SLL in the lymph nodes and primary mucinous adenocarcinoma of the lung. Evidence shows a heightened risk of second primary neoplasms in CLL/SLL, particularly among patients exposed to alkylating agents. This case emphasizes the role of demographic and treatment-related factors—such as male sex, advanced age, smoking history, and therapeutic regimens—in secondary cancer development. Vigilant monitoring and a multidisciplinary approach tailored to individual risk are essential for early detection and optimal management in this population.
No takes yet. Share an insight, caveat, or question.
Fernández‐Trujillo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: